A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
暂无分享,去创建一个
Leif Bertilsson | M. Ingelman-Sundberg | L. Bertilsson | M. Dahl | E. Aklillu | Sarah C. Sim | Carl Risinger | Marja‐Liisa Dahl | Eleni Aklillu | Magnus Christensen | Magnus Ingelman‐Sundberg | C. Risinger | M. Christensen | S. Sim
[1] H. Sugimura,et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. , 2001, Pharmacogenetics.
[2] 杉本 光繁. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status , 2006 .
[3] M. Ingelman-Sundberg,et al. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. , 1996, Pharmacogenetics.
[4] J Licinio,et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.
[5] H. Nakabayashi,et al. A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma , 1991, Molecular and cellular biology.
[6] U. Brinkmann,et al. Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19. , 2003 .
[7] L. Bertilsson,et al. No sex‐related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects , 2000, Clinical pharmacology and therapeutics.
[8] M. Ingelman-Sundberg,et al. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. , 2002, Pharmacogenetics.
[9] L. Bertilsson,et al. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. , 2003, British journal of clinical pharmacology.
[10] L. Bertilsson,et al. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. , 1995, Pharmacogenetics.
[11] Ulrich Klotz,et al. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole‐based quadruple therapy for eradication of Helicobacter Pylori , 2004, Clinical pharmacology and therapeutics.
[12] D. Charney,et al. Treatment‐refractory depression: Definitions and characteristics , 1997, Depression and anxiety.
[13] H. Mohrenweiser,et al. Identification and functional characterization of new potentially defective alleles of human CYP2C19. , 2002, Pharmacogenetics.
[14] D. Flockhart,et al. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.
[15] R. A. Zeeuw,et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences , 1999, European Journal of Clinical Pharmacology.
[16] Kyoichi Ohashi,et al. Pharmacogenomics of proton pump inhibitors. , 2004, Pharmacogenomics.
[17] K. Shimoda,et al. Clinical significance of plasma levels of clomipramine, its hydroxylated and desmethylated metabolites: prediction of clinical outcome in mood disorders using discriminant analysis of therapeutic drug monitoring data. , 1993, Journal of affective disorders.
[18] L. Bertilsson,et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. , 1995, British journal of clinical pharmacology.
[19] Zhaoqian Liu,et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19 , 2001, Clinical pharmacology and therapeutics.
[20] K Walsh,et al. The human GATA-6 gene: structure, chromosomal location, and regulation of expression by tissue-specific and mitogen-responsive signals. , 1996, Genomics.
[21] P. Nelemans,et al. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review , 2004, Molecular Psychiatry.
[22] M. Ingelman-Sundberg,et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine , 2004, European Journal of Clinical Pharmacology.
[23] Yoshiro Saito,et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. , 2004, Drug metabolism and pharmacokinetics.
[24] K. Ohashi,et al. Effect of high‐dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19 , 2001, Clinical pharmacology and therapeutics.
[25] J. D. Engel,et al. Hepatic Erythropoietin Gene Regulation by GATA-4* , 2004, Journal of Biological Chemistry.
[26] L. Bertilsson,et al. The karolinska cocktail for phenotyping of five human cytochrome P450 enzymes , 2003, Clinical pharmacology and therapeutics.
[27] E. Sellers,et al. Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker , 2002, Clinical pharmacology and therapeutics.
[28] Daniel Levy,et al. Regulation of human microsomal epoxide hydrolase gene (EPHX1) expression by the transcription factor GATA-4. , 2004, Biochimica et biophysica acta.
[29] T. Koike,et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism , 2003, Alimentary pharmacology & therapeutics.
[30] M. Kasuga,et al. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. , 2002, Biological & pharmaceutical bulletin.
[31] A. Chow,et al. Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene‐Dose Effect and Intrasubject Variability , 2004, Journal of clinical pharmacology.
[32] D. Yim,et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19 , 2001, Clinical pharmacology and therapeutics.
[33] H. Sackeim,et al. Sertraline treatment of elderly patients with depression and cognitive impairment , 2003, International journal of geriatric psychiatry.
[34] M. Relling,et al. Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.
[35] L. Bertilsson,et al. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. , 2000, Gastroenterology.
[36] H. Sugimura,et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. , 2000, Clinical pharmacology and therapeutics.
[37] K. Ohashi,et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole , 2002, Clinical pharmacology and therapeutics.
[38] Kyoichi Ohashi,et al. Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.
[39] Zhaoqian Liu,et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[40] David B. Wilson,et al. GATA-4, GATA-5, and GATA-6 activate the rat liver fatty acid binding protein gene in concert with HNF-1alpha. , 2004, American journal of physiology. Gastrointestinal and liver physiology.
[41] K. Ohashi,et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH , 2001, Alimentary pharmacology & therapeutics.
[42] T Ishizaki,et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. , 1998, Clinical pharmacology and therapeutics.
[43] U. Klotz,et al. CYP2C19 polymorphism and proton pump inhibitors. , 2004, Basic & clinical pharmacology & toxicology.
[44] H. Sugimura,et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin , 2001 .